The Valley Desk

NCT02581410 · Interventional trial

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

Overall registry status Completed

Phase 3

Conditions Herpes Zoster

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov